Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In the News
  • Published:

HIV vaccine results controversy

Nature Reviews Immunology volume 9, page 755 (2009)Cite this article

An announcement, by researchers from the US Army and Thailand, at a recent press conference of the first positive results from an HIV vaccine trial was met with media fanfare but cautious optimism from scientists.

The RV 144 vaccine, which combines two vaccines (ALVAC and AIDSVAX) that alone were unsuccessful in previous clinical trials, showed moderate success at preventing HIV infection. Seventy-four of the 8,198 people who received the placebo became infected with HIV, compared with 51 of the 8,197 vaccinated individuals: a statistically significant 31% protection efficacy ( Nature News , 24 Sep 2009).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Olive Leavy
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leavy, O. HIV vaccine results controversy. Nat Rev Immunol 9, 755 (2009). https://doi.org/10.1038/nri2668

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nri2668

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing